头孢哌酮/舒巴坦与左氧氟沙星治疗老年支气管扩张急性加重患者的有效性和安全性比较

To Compare the Efficacy and Safety of Cefoperazone/Sulbactam and Levofloxacin in the Treatment of Patients With Senile Acute Exacerbation Bronchiectasis

目的比较头孢哌酮/舒巴坦与左氧氟沙星治疗老年支气管扩张急性加重患者的有效性和安全性。方法将90例符合标准的老年支气管扩张急性加重期患者随机分为观察组和对照组,分别采用头孢哌酮/舒巴坦治疗和左氧氟沙星治疗,比较临床疗效和安全性。结果治疗前,两组白细胞计数和中心粒细胞百分比对比,差异无统计学意义(P>0.05);治疗后上述指标均有所改善,但观察组改善程度大于对照组,差异具有统计学意义(P<0.05)。观察组总有效率88.9%优于对照组(68.9%),差异具有统计学意义(P<0.05)。结论头孢哌酮舒巴坦治疗老年支气管扩张急性加重期患者疗效更好,不良反应小,安全性较高。

Objective To compare the Cefoperazone/sulbactam and levolfoxacin in the treatment of senile bronchiectasis in acute exacerbation of the efficacy and safety of patients.Methods90 cases of senile acute exacerbation bronchiectasis patients were randomly divided into observation group and control group, respectively with Cefoperazone/sulbactam and levolfoxacin in the treatment of treatment and compare the clinical efficacy and safety of the two groups before treatment.Results The white blood cell count and neutrophil percentage had no significant difference （P 〉 0.05）. After treatment, the above indexes were improved, but the observation group was better than the control group, the difference was statistically signiifcant （P〈0.05）. The total effciency of the observation group was better than that of the control （88.9%） group （68.9%） （P 〈 0.05）.Conclusion Cefoperazone sulbactam in the treatment of senile acute exacerbation bronchiectasis patients with better curative effect, less adverse reaction, high safety.